Identification of CD15 as a Marker for Tumor-Propagating Cells in a Mouse Model of Medulloblastoma  by Read, Tracy-Ann et al.
Cancer Cell
ArticleIdentification of CD15 as a Marker
for Tumor-Propagating Cells
in a Mouse Model of Medulloblastoma
Tracy-Ann Read,1,5 Marie P. Fogarty,1 Shirley L. Markant,1 Roger E. McLendon,2,3 Zhengzheng Wei,4 David W. Ellison,6
Phillip G. Febbo,4 and Robert J. Wechsler-Reya1,3,*
1Department of Pharmacology and Cancer Biology
2Department of Pathology
3Preston Robert Tisch Brain Tumor Center
4Institute for Genome Sciences & Policy
Duke University Medical Center, Durham, NC 27710, USA
5Department of Biomedicine, University of Bergen, Bergen N-5009, Norway
6Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
*Correspondence: rw.reya@duke.edu
DOI 10.1016/j.ccr.2008.12.016
SUMMARY
The growth of many cancers depends on self-renewing cells called cancer stem cells or tumor-propagating
cells (TPCs). In human brain tumors, cells expressing the stem cell marker CD133 have been implicated as
TPCs. Here we show that tumors from a model of medulloblastoma, the Patchedmutant mouse, are propa-
gated not by CD133+ cells but by cells expressing the progenitor markers Math1 and CD15/SSEA-1. These
cells have a distinct expression profile that suggests increased proliferative capacity and decreased
tendency to undergo apoptosis and differentiation. CD15 is also found in a subset of human medulloblas-
tomas, and tumors expressing genes similar to those found in murine CD15+ cells have a poorer prognosis.
Thus, CD15 may represent an important marker for TPCs in medulloblastoma.INTRODUCTION
The growth of many tumors has been suggested to depend on
a subset of tumor cells with an extensive capacity for self-
renewal, termed cancer stem cells, tumor-initiating cells, or
tumor-propagating cells (TPCs) (Huntly and Gilliland, 2005;
Reya et al., 2001). These cells are not necessarily abundant or
highly proliferative, but because they are long lived and often
resistant to conventional therapies (Bao et al., 2006; Liu et al.,
2006; Singh et al., 2004), they are believed to contribute to tumor
resistance and recurrence. Therefore, identifying these cells and
finding approaches to targeting them has become an important
goal in cancer biology.
TPCs were originally described in leukemia, where it was
shown that a rare population of cells resembling hematopoietic
stem cells were uniquely capable of propagating tumors
following transplantation (Bonnet and Dick, 1997). Cells with
similar properties have been identified in breast cancer, prostate
cancer, and other solid tumors (Al-Hajj et al., 2003; O’Brien et al.,
2007; Singh et al., 2004; Xin et al., 2005). In many cases, TPCs
express markers associated with stem cells from the corre-
sponding tissue and are capable of generating multiple cell types
from that tissue. But a stem-like phenotype is not a necessary
feature of TPCs: even cells that do not express stem cell markers
or exhibit multipotent differentiation can propagate tumors
(Krivtsov et al., 2006; Peacock et al., 2007). Drawing a distinction
between stem-like cancer cells and cancer stem cells (TPCs) is
essential for interpreting studies in this field.
Evidence for TPCs in brain tumors first came from the obser-
vation that human medulloblastomas, astrocytomas, and epen-
dymomas contain cells that express the neural stem cell marker
CD133 (Hemmati et al., 2003; Singh et al., 2003). Like normal
SIGNIFICANCE
Although tumor-propagating cells (TPCs) have been described in human brain tumors, such cells have not been identified in
mouse models of the disease. Finding TPCs in mouse models is critical because it allows studies of their developmental
origins and experimental manipulation and targeting of these cells in a species-matched microenvironment. Here we iden-
tify a population of TPCs in a model of medulloblastoma and show that these cells express CD15 (also known as SSEA-1 or
LeX) and resemble neural progenitors. Our data challenge the notion that all brain tumors are propagated by stem-like cells
and raise the possibility that CD15 may be used to identify and target TPCs in human brain tumors.
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Propagation of Medulloblastoma by CD15+ Cellsstem cells, these cells can form ‘‘neurospheres’’ that can be
passaged repeatedly and induced to differentiate into neurons
and glia (Hemmati et al., 2003; Singh et al., 2003; Taylor et al.,
2005). Most importantly, these cells are highly enriched for
tumor-propagating capacity: CD133+ cells can generate tumors
in immunocompromised mice, whereas CD133 cells cannot
(Singh et al., 2004; Taylor et al., 2005). CD133+ cells from human
gliomas have also been shown to be resistant to radiation and
chemotherapy (Bao et al., 2006; Liu et al., 2006). These data
suggest thatCD133+ cells representTPCs for humanbrain tumors.
Although TPCs have been studied in human brain tumors,
such cells have not been identified in mouse models of these
tumors. Identifying mouse counterparts of TPCs is important
since it allows studies of their origin and development as well
as experimental manipulation and targeting of these cells in
a species-matched (murine) microenvironment. This is critical
in light of recent studies suggesting that the xenotransplantation
assay used to identify human TPCs may select for cells that can
survive in a foreign host and may therefore lead to underestima-
tion or incorrect identification of TPCs (Kelly et al., 2007).
We sought to identify TPCs in a widely used model of medul-
loblastoma, the Patched (Ptc) mutant mouse (Goodrich et al.,
1997).Ptc encodes an antagonist of the Hedgehog (Hh) signaling
pathway (Rohatgi and Scott, 2007). Germline mutations in Ptc
result in Gorlin syndrome, a hereditary disorder associated
with skin tumors, craniofacial abnormalities, and an increased
incidence of medulloblastoma (Hahn et al., 1996; Johnson
et al., 1996). Among sporadic medulloblastomas, 15%–25%
also contain mutations in Ptc or other elements of the Hh
pathway (Pietsch et al., 1997; Taylor et al., 2002; Thompson
et al., 2006). Although homozygous Ptc knockout mice die
during embryogenesis, Ptc heterozygotes (Ptc+/ mice) survive
to adulthood, and 15%–20% develop tumors that resemble
human medulloblastoma (Goodrich et al., 1997). These animals
have provided insight into the early stages of tumorigenesis
(Oliver et al., 2005), the genes that cooperate with loss of Ptc
to promote tumor progression (Pogoriler et al., 2006; Uziel
et al., 2005; Wetmore et al., 2001), and the efficacy of Hh antag-
onists in treating the disease (Berman et al., 2002; Romer et al.,
2004). However, they have not been used to study the cells
responsible for tumor propagation.
Here we show that tumors from Ptc+/ mice are propagated
not by stem-like CD133+ cells but by cells expressing the
neuronal progenitor marker Math1 and the carbohydrate antigen
CD15. CD15+ cells are also found in a subset of human medullo-
blastomas, and expression of genes similar to those found in
murine CD15+ cells (a ‘‘CD15+ signature’’) predicts patient
survival. These studies identify CD15 as a marker for TPCs in
Ptc+/ mice and raise the possibility that a similar population of
cells may be important for growth or maintenance of human
medulloblastoma.
RESULTS
Medulloblastomas from Ptc+/ Mice Can Be Propagated
by Orthotopic Transplantation
To identify TPCs in Ptc+/ tumors, we established an orthotopic
transplantation assay. Tumor cells were isolated from Ptc+/
mice and immediately stereotaxically implanted into the cere-
bellum of SCID/beige hosts. As shown in Figures 1A and 1B,
implantation of 13 106 tumor cells resulted in secondary tumors
that histologically resembled the primary tumors from which the
cells were derived. In particular, both primary and secondary
tumors consisted of small round cells with little cytoplasm and
clearly demarcated borders, as is the case for many human
medulloblastomas. To determine how many cells were required
to generate tumors, we repeated these experiments using
varying numbers of cells. When animals were transplanted with
50,000 or 100,000 cells, only a subset of recipients (17% and
42%, respectively) developed tumors, and the latency of tumor
formation was variable. In contrast, animals receivingR200,000
tumor cells showed 100% tumor incidence, with a median latency
of 49 days (Figure 1C). These data demonstrate thatPtc+/ tumors
can be propagated by transplantation into the cerebellum.
Ptc+/ Medulloblastomas Are Not Propagated
by CD133+ Cells
Since CD133+ cells have been shown to be critical for propaga-
tion of human brain tumors (Singh et al., 2004), we examined
whether a similar population of cells was present in tumors
from Ptc+/ mice. As shown in Figures 2A and 2B, CD133
expression varied greatly among Ptc+/ tumors, with most
tumors containing <5% CD133+ cells but some containing as
many as 56% CD133+ cells (median = 2.5%). In general, tumors
in the posterior cerebellum (adjacent to the brainstem) had
higher levels of CD133 than those in anterior regions.
Figure 1. Propagation of Ptc+/ Tumor Cells by Orthotopic Trans-
plantation
Tumor cells were implanted into the cerebellum of SCID/beige hosts. Animals
were sacrificed when they developed symptoms, and tumor tissues were
stained with hematoxylin and eosin (H&E).
(A) Primary tumor from a Ptc+/ mouse.
(B) Secondary tumor from a SCID/beige host that received 5 3 105 Ptc+/
tumor cells. Scale bars in (A) and (B) = 100 mm.
(C) Tumor-free survival of animals receiving the indicated numbers of Ptc+/
tumor cells. Animals implanted with 2–5 3 105 cells developed tumors within
6–8 weeks (median latency 49 days). Animals implanted with 0.5 3 105 or
13 105 cells developed tumors with a lower incidence (42% and 17%, respec-
tively) and a longer latency (58 days and 159 days, respectively).
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Propagation of Medulloblastoma by CD15+ CellsFigure 2. CD133 Does Not Mark Tumor-Propagating Cells in Ptc+/ Tumors
(A and B) Tumor cells from Ptc+/ or Math1-GFP/Ptc+/ mice were stained with anti-CD133 (black histograms) or isotype-matched control antibodies (gray
histograms) and analyzed by fluorescence-activated cell sorting (FACS).
(A) Representative histograms from CD133lo (top) and CD133hi (bottom) tumors.
(B) Scatter plot showing percentage of CD133+ cells in 24 tumors. Horizontal line indicates median percentage of CD133+ cells (2.5%).
(Cand D)CD133+ cellswere sorted from neonatal cerebellum (C)or fromPtc+/ tumors (D) and cultured atclonaldensity in serum-free mediumwith 25 ng/mlEGFand
bFGF for 10 days. Cells were photographed under bright field (upper images; scale bar = 200 mm) or stained using a live/dead assay kit, which labels live cells green
and dead cells red (lower images; scale bar = 100mm). Passageable neurospheres were consistently obtained from neonatal cerebellum, but not fromPtc+/ tumors.
(E) Survival of SCID/beige mice implanted with 3 3 105 unsorted, CD133+, or CD133 tumor cells.
(F and G) Tumors did not develop in mice implanted with CD133+ cells (cerebellum shown in [F]) but developed in all mice implanted with CD133 cellsCD133+ cells from human brain tumors, like normal neural
stem cells, have been reported to generate neurospheres
when cultured at low density in the presence of growth factors
(Hemmati et al., 2003; Singh et al., 2003). To test whether this
was true for CD133+ cells from Ptc+/ tumors, we cultured these
cells at clonal density (200 cells/ml) in serum-free medium con-
taining epidermal and fibroblast growth factors. Under these
conditions, CD133+ cells from neonatal mouse cerebellum
reproducibly generated neurospheres (Figure 2C), and these
spheres could be passaged repeatedly in vitro (Lee et al., 2005
and data not shown). In contrast, CD133+ cells from Ptc+/
tumors did not generate neurospheres at clonal density
(Figure 2D). At higher density (40,000–80,000 cells/ml), CD133+
cells formed multicellular aggregates within 24 hr. However,
the viability of these cells declined dramatically over the next
5–7 days, and cells could not be maintained or expanded by
passaging. Similar results were observed with unsorted Ptc+/
tumor cells. These results suggest that CD133+ cells from Ptc+/
tumors do not form neurospheres.
To determine whether CD133+ cells were capable of tumor
propagation, we used an orthotopic transplantation assay.
Ptc+/ tumor cells were sorted into CD133+ and CD133 frac-
tions, and 300,000 cells from each fraction were transplanted
into the cerebellum of SCID/beige mice. As shown in
Figure 2E, 100% of the mice that received unsorted cells or
CD133 cells developed tumors between 6 and 8 weeks
(Figure 2G). In contrast, animals that received CD133+ cells did
not develop tumors, and no remnants of these cells could be de-
tected by hematoxylin and eosin staining >8 months after trans-
plantation (Figure 2F). Since Ptc+/ tumor cells contain a
b-galactosidase (b-gal) transgene (Goodrich et al., 1997), we
also stained cerebella from animals transplanted with CD133+
cells with anti-b-gal antibodies; this approach also failed to
detect CD133+ cells at the time of sacrifice (data not shown).
These results suggest that Ptc+/ tumors are propagated by
CD133 rather than CD133+ cells.
Ptc+/ Tumors Are Propagated by Cells Expressing
the Progenitor Marker Math1
Since CD133+ cells could not generate tumors following trans-
plantation, we looked for other possible markers of TPCs in
Ptc+/ tumors. We and others (Lee et al., 2003; Oliver et al.,
2005) have shown that many Ptc+/ tumor cells express the tran-
scription factor Math1, a marker of immature granule neuron
precursors (GNPs). To determine whether tumors are propa-
gated by Math1+ cells, we used Math1-GFP/Ptc+/ mice, in
(cerebellum with tumor shown in [G]). Scale bars = 200 mm.
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Propagation of Medulloblastoma by CD15+ Cellswhich Math1-expressing cells express green fluorescent protein
(Lumpkin et al., 2003). Consistent with previous findings (Oliver
et al., 2005), 80%–95% of tumor cells from these animals ex-
pressed GFP (Figure 3A). To assess the tumorigenicity of these
cells, we sorted GFP+ and GFP cells and transplanted them
into the cerebellum of SCID/beige mice. GFP+ cells gave rise
to tumors in all recipients (Figure 3B), and these tumors resem-
bled donor tumors in terms of GFP expression (Figures 3C and
3D) and proliferative index (Ki67, Figures 3E and 3F). In contrast,
none of the recipients of GFP cells developed tumors. Thus, the
tumor-propagating cell in Ptc+/ medulloblastoma is contained
within the GNP-like Math1-GFP+ population.
The Tumor-PropagatingCell inPtc+/Medulloblastomas
Expresses CD15
Since the majority of Ptc+/ tumor cells express Math1-GFP,
sorting for these cells does not significantly enrich for TPCs. To
identify other possible markers of TPCs within the Math1-GFP+
population, we stained Ptc+/ and Math1-GFP/Ptc+/ tumors
with antibodies previously shown to mark neural progenitors
and stem cells. Figure S1A available online shows the markers
tested and the expression range in the tumors we screened.
Among these markers, several (A2B5, PSA-NCAM, CD24,
CD44, Sca-1, and CD117/c-kit) were not consistently expressed
and were excluded from further analysis. Three markers—HNK1,
CD15, and GD3—were found in all tumors examined and were
tested to determine whether they could enrich for TPCs. Tumor
cells lacking or expressing these markers were isolated by fluo-
rescence-activated cell sorting (FACS) and transplanted into the
cerebellum of SCID/beige mice. As shown in Figure S1B, tumors
developed with similar frequency in animals that received HNK1+
and HNK1 cells, indicating that this marker could not be used
for enrichment. Animals transplanted with GD3+ cells did not
develop tumors, whereas those transplanted with GD3 cells
did (Figure S1C). However, since 92%–99% of tumor cells lack
GD3, selecting for GD3 cells did not result in substantial enrich-
ment of the tumor-propagating population.
The only marker we tested that consistently enriched for tumor
propagation was CD15. Also known as stage-specific embry-
onic antigen-1 (SSEA-1), Lewis X (LeX), or FORSE-1 (Allendoer-
fer et al., 1995; Capela and Temple, 2002; Solter and Knowles,
1978), CD15 is a carbohydrate epitope expressed on normal
neutrophils (Skubitz and Snook, 1987), Hodgkin’s lymphoma
cells (Hall and D’Ardenne, 1987), and cells from a variety of solid
cancers (Fox et al., 1983; McCarthy et al., 1985). In addition,
several studies suggest that it is expressed on stem cells and
progenitors in the embryonic and adult nervous system (Allen-
doerfer et al., 1995; Capela and Temple, 2002; Capela and
Temple, 2006). As shown in Figure 4A, CD15+ cells consistently
gave rise to tumors, whereas CD15 cells did not. These studies
suggested that CD15 marks TPCs in tumors from Ptc mutant
mice.
CD15 Is Expressed on a Subset of Granule Neuron
Precursors and Tumor Cells
CD15 is expressed on stem cells and tumor cells from a variety of
tissues. Although its expression has been reported in the cere-
bellum (Ashwell and Mai, 1997; Marani and Tetteroo, 1983), its
localization and function during cerebellar development are
unknown. To determine whether CD15 is expressed on GNPs,
we isolated cerebellar cells from neonatal Math1-GFP mice,
stained them with anti-CD15 antibodies, and analyzed them by
FACS. As we have shown previously (Lee et al., 2005), the
majority of cells that can be isolated from the cerebellum at post-
natal day 7 (P7) are Math1-GFP+ (Figure 4B); of these, 15%–20%
coexpress CD15. Staining of sections of neonatal cerebellum
revealed CD15 expression in the white matter as well as on
a proportion of GNPs in the external germinal layer (Figure S2).
Thus, a subset of GNPs expresses CD15.
To characterize expression of CD15 in Ptc+/ tumors, we
stained tumor cells from a large cohort of Ptc+/ and Math1-
GFP/Ptc+/ mice with anti-CD15 antibodies. FACS analysis re-
vealed CD15 expression in all tumors (Figure 4D), although there
was marked tumor-to-tumor variation in the percentage of
CD15+ cells (Figure 4C). In general, tumors from Math1-GFP/
Ptc+/ mice contained fewer CD15+ cells (median = 4.3%) than
Figure 3. Ptc+/ Tumors Are Propagated by Math1+ Cells
(A) FACS analysis of tumors from Math1-GFP/Ptc+/ mice shows that the
majority of tumor cells are Math1-GFP+.
(B) Survival of SCID/beige mice implanted with 3 3 105 GFP+ or GFP cells.
Tumors developed in 100% of animals implanted with GFP+ cells (median
latency 48 days).
(C–F) Tumors from Math1-GFP/Ptc+/ mice (1 tumors in [C] and [E]) and from
SCID/beige mice implanted with Math1-GFP/Ptc+/ tumor cells (2 tumors in
[D] and [F]) were cryosectioned and stained with DAPI (blue) to label nuclei
and with anti-GFP antibodies (green) to label Math1-expressing cells ([C]
and [D]). Additional tumors were paraffin embedded, sectioned, and stained
with hematoxylin (blue) to label nuclei and with anti-Ki67 (brown) to label prolif-
erating cells ([E] and [F]). Scale bars = 200 mm.
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Propagation of Medulloblastoma by CD15+ Cellsthose from Ptc+/ mice (median = 47%); this may reflect differ-
ences in the strain backgrounds of these mice (see Experimental
Procedures). Importantly, the CD15+ population in Math1-GFP/
Ptc+/ tumors was predominantly GFP+, consistent with the
notion that TPCs express Math1 (Figures 4C and 4D; Figure S3).
Staining of tumor sections showed CD15+ cells scattered
throughout the tumor, but with a higher density near the surface
of the cerebellum and at the boundary between tumor and normal
tissue (Figures 4E and 4F). The fact that a subset of cells within
every tumor expressed CD15 and the fact that only these cells
were capable of forming tumors following transplantation sug-
gested that CD15 marks TPCs in Ptc+/ medulloblastoma.
CD15+ Cells Recapitulate the Heterogeneity
of Ptc+/ Medulloblastoma
A cardinal feature of TPCs is their ability to regenerate all of the
cell types in the original tumor. To determine whether CD15+
cells could recapitulate the heterogeneity of the tumor from
which they were isolated, we analyzed tumors formed following
transplantation of CD15+ cells. As shown in Figures S4A and
S4B, tumors resulting from transplantation of CD15+ cells histo-
logically resembled the tumors from which they were derived.
Secondary tumors from Math1-GFP/Ptc+/ mice consisted
largely of Math1-GFP+ cells (Figures S4C and S4D), indicating
that the overall phenotype of the tumor did not change following
transplantation. Moreover, secondary tumors contained CD15+
and CD15 cells in proportions similar to those found in the
primary tumor (Figures S4E and S4F). These studies indicate
that upon transplantation, CD15+ cells not only generate more
of themselves but also give rise to the other cell types that
make up a histologically complex tumor.
CD15+ Cells Have a Distinct Gene Expression Profile
Having observed a marked difference in the ability of CD15+ and
CD15 cells to generate tumors, we sought to determine the
molecular basis for this difference. To this end, we isolated
RNA from CD15+ and CD15 cells and performed microarray
analysis. Principal components analysis (PCA), a statistical
method that facilitates global comparison of gene expression
between multiple samples, indicated that CD15+ and CD15
cells were readily distinguishable from one another (Figure 5A).
Differences between CD15+ and CD15 cells were also apparent
from hierarchical clustering (Figure 5B), which revealed groups
of genes whose expression was increased or decreased in
CD15+ versus CD15 cells. Among the 45,101 probe sets on
the arrays, 438 (approximately 1%) showed significant differ-
ences in expression (increased or decreased byR1.8-fold, false
discovery rate [FDR] < 0.05 by paired t test) between these pop-
ulations. Of these, 70 were higher in CD15+ cells, and 368 were
lower (see Table S1).
To gain insight into the properties that distinguish CD15+ and
CD15 cells, we performed Gene Ontology analysis (Table S2)
and carried out literature searches for each of the differentially
expressed genes, focusing in particular on their functions in
the nervous system. Based on this analysis, we identified five
major categories of genes that were differentially expressed
between CD15+ and CD15 cells (see Table 1 and Table S3).
Regulators of proliferation and self-renewal (e.g., Cyclins B1
and B2, Aurora kinase, and Notch2) accounted for the majority
of genes upregulated in CD15+ cells. Expression of proapoptotic
genes (including those encoding the ubiquitin ligase Fbxo7, the
Bcl-2-interacting protein harakiri, and the apoptosis-inducing
Figure 4. CD15 Is Expressed on a Subset of Medulloblastoma Cells
and Enriches for Tumor Propagation
(A) Tumor cells from Ptc+/ or Math1-GFP/Ptc+/ mice were stained with anti-
CD15 antibodies and sorted into CD15+ and CD15 fractions. 3 3 105 cells
from each fraction were implanted into SCID/beige mice, and animals were
monitored for tumor formation. Animals transplanted with CD15+ cells all
developed tumors, whereas those transplanted with CD15 cells did not.
(B) Expression of CD15 in neonatal cerebellum. Cerebellar cells from P7
Math1-GFP mice were stained with anti-CD15 antibodies and analyzed by
FACS. Among cells that expressed Math1-GFP (right quadrants), a subset
(15% of all cells, 18.5% of Math1-GFP+ cells) expressed CD15 (red dots).
(C) Scatter plot showing the percentage of CD15+ cells in a panel of 34 Ptc+/
tumors (black dots) and 13 Math1-GFP/Ptc+/ tumors (green dots). Horizontal
lines indicate median percentage of CD15+ cells: 47% for Ptc+/ and 4.3% for
Math1-GFP/Ptc+/ tumors.
(D–F) Expression of CD15 in Ptc+/ tumor cells.
(D) FACS analysis of CD15 expression in a representative Math1-GFP/Ptc+/
tumor. Among tumor cells expressing Math1-GFP (right quadrants), 13.4%
(11% of all tumor cells) expressed CD15 (red dots).
(E and F) Tumor-bearing Math1-GFP/Ptc+/ mice (E) and Ptc+/ mice (F) were
injected intracranially with anti-CD15-secreting hybridomas to label CD15+
cells in vivo (see Supplemental Experimental Procedures). Cerebella were
sectioned and stained with secondary antibodies to detect cells that had
bound anti-CD15 antibodies (red) and with anti-GFP antibodies to label
Math1-expressing cells (green) or with DAPI (blue) to label all nuclei. Note
the predominance of CD15 staining on the edge of the tumor (E) and at the
boundary between tumor and normal tissue (F). Scale bars = 100 mm.
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CD15 cells, while the antiapoptotic protein Birc5/survivin was
higher. Genes implicated in cell migration and axon growth
(including L1CAM, Contactin2/Tag-1, Semaphorin 6A, and Dou-
blecortin) were also significantly decreased in CD15+ cells,
consistent with the notion that these cells have a decreased
propensity to migrate away from the surface of the cerebellum
and elaborate axons, processes associated with normal granule
neuron differentiation. Finally, the list of differentially expressed
genes included a significant number of RNA-binding proteins
(which regulate mRNA processing and stability), transcription
factors, and regulators of chromatin structure. While some of
these (NeuroD1, Nhlh1/Nscl, Elavl4/HuD, and Actin-like 6b/
Baf53b) have been shown to regulate differentiation in GNPs
and other types of neurons, the function of most remains to be
determined. Differential expression of selected genes from
each of these categories was validated by quantitative RT-
PCR (Figure 5C). Overall, these data indicate that CD15+ and
CD15 cells have distinct gene expression profiles and that the
tumor-propagating capacity of CD15+ cells is associated with
an increased capacity to proliferate and a decreased tendency
to undergo apoptosis and differentiation.
CD15+ Cells Exhibit Increased Hh Pathway Activation
and Proliferation
TPCs in human leukemia are more quiescent than the blasts that
make up the majority of the tumor (Bonnet and Dick, 1997; Holy-
oake et al., 1999). In contrast, brain tumor stem cells have been
reported to exhibit higher proliferation than nonstem cells from
the same tumor (Singh et al., 2003, 2004). The fact that CD15+
cells from Ptc+/ tumors expressed elevated levels of cell-cycle
regulators suggested that these cells might also be more prolif-
erative than CD15 cells. To examine this, we sorted CD15+ and
CD15 cells from Ptc+/ tumors, cultured them for 48 hr, and
measured incorporation of tritiated thymidine. As shown in
Figure 6A, CD15+ cells consistently showed a higher level of
thymidine incorporation than CD15 cells from the same tumor.
(These studies involved culturing cells at high density in the
absence of added growth factors; when cells were cultured at
clonal density in the presence of epidermal growth factor [EGF]
Figure 5. CD15+ Cells Have a Distinct Gene Expression Profile
Cells from six Ptc+/ tumors were sorted into CD15+ and CD15 samples, and RNA from these samples was labeled and hybridized to Affymetrix expression
microarrays.
(A) Principle components analysis (PCA). Each sample is represented by a spot (red = CD15+, blue = CD15), whose position in the grid reflects its overall expres-
sion profile. The distance between spots is proportional to the difference in gene expression. Note that CD15+ samples are clustered together (red ellipse) and
occupy a region of the grid distinct from that occupied by CD15 samples (blue ellipse).
(B) Unsupervised hierarchical clustering highlights groups of genes whose expression is significantly increased or decreased in CD15+ versus CD15 cells. Each
column represents a distinct sample (CD15 or CD15+), and each row represents an individual gene. The normalized relative level of gene expression is denoted
by color (blue = low, gray = intermediate, red = high) as indicated in the gradient at the bottom.
(C) Validation of differential gene expression by RT-PCR. CD15+ and CD15 samples from five independentPtc+/ tumors (distinct from those used for microarray
analysis) were analyzed by quantitative RT-PCR using primers for the indicated genes. Gene expression was normalized based on actin levels.
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did not form neurospheres, and showed no evidence of multiline-
age differentiation). CD15+ cells also showed increased prolifer-
ation in vivo, as measured by incorporation of bromodeoxyuri-
dine (BrdU; Figure S5). Together, these data suggest that
CD15+ cells have an increased capacity for proliferation in vitro
and in vivo.
Since proliferation of medulloblastoma cells from Ptc+/ mice
is dependent on Hh pathway activation (Berman et al., 2002; Ro-
mer et al., 2004) we also examined expression of Hh target genes
in CD15+ and CD15 tumor cells. As shown in Figures 6B and
6C, CD15+ cells expressed elevated levels of the Hh target genes
Cyclin D1 and Gli1 (Kenney and Rowitch, 2000; Oliver et al.,
2003) compared to CD15 cells. Interestingly, CD15+ cells iso-
lated from the neonatal cerebellum also showed greater target
gene induction and a stronger proliferative response to Sonic
hedgehog than CD15 cells (data not shown). These data
suggest that increased proliferative capacity of CD15+ cells is
associated with increased Hh pathway activation.
One explanation for the low proliferative capacity of CD15
cells and the inability of these cells to propagate tumors could
be that they do not represent tumor cells at all. Among the
features that have been used to define tumor cells in the Ptc
mutant mouse are expression of Math1 (a marker of GNPs that
is not expressed in the normal adult cerebellum) and loss of
the remaining (wild-type [WT]) copy ofPtc (Lee et al., 2003; Oliver
et al., 2005). The fact that a substantial proportion of CD15 cells
express Math1 (see Figures 5C and 5E) suggests that these cells
represent tumor cells, rather than normal cells that have become
trapped within the tumor. To determine whether these cells have
also lost expression of WT Ptc, we analyzed RNA from
Math1+CD15+ and Math1+CD15 tumor cells by real-time RT-
PCR. To distinguish between WT and mutant Ptc transcripts,
we used two sets of primers: one derived from exons 7–9, which
are present in both WT and mutant alleles, and another derived
from exons 2–3, which can only amplify sequences present in
the WT allele (Oliver et al., 2005). As shown in Figure 6D, tran-
scripts containing exons 7–9 were found in CD15+ and CD15
tumor cells, as well as in normal GNPs (a positive control for
Ptc expression). In contrast, transcripts containing exons 2–3
(specific for the WT allele) were observed in GNPs but were
absent from both CD15+ and CD15 tumor cells. These results
suggest that CD15 cells are tumor cells but simply lack
tumor-propagating capacity.
CD15 Is Expressed in a Subset of Human
Medulloblastomas
The fact that CD15 identified TPCs in murine medulloblastoma
raised the possibility that it might be important in human tumors
as well. To determine whether CD15 is expressed in human
medulloblastoma, we performed immunohistochemical analysis
on a panel of archival medulloblastoma samples. Immunoreac-
tivity for CD15 in granulocytes and histiocytes was detected in
all cases, serving as an internal control. CD15+ tumor cells
were present in approximately one-third of cases (10 of 28
samples), including classic and large-cell tumors and medullo-
blastomas with extensive nodularity (Figures 7A–7C). CD15
staining was also detected in patient samples analyzed by flow
cytometry (data not shown), including one nodular medulloblas-
toma, one tumor with focal nodularity, and one large-cell tumor.
These data indicate that CD15 is expressed in a subset of human
medulloblastomas.
To gain insight into the clinical significance of CD15 expres-
sion, we took advantage of the gene expression analysis we
had performed on murine tumors. Using the genes that were
differentially expressed in CD15+ versus CD15 cells from
Ptc+/ tumors and published methods (Bild et al., 2006), we iden-
tified a set of genes (a ‘‘CD15+ signature’’) whose expression
robustly predicted the CD15 status of our samples (see
Figure S6 and Table S4). The validity of this signature was
confirmed in proper leave-one-out cross-validation of our orig-
inal samples (see Supplemental Experimental Procedures) and
when applied to an independent set of tumors sorted for CD15
status. The CD15+ signature was then used to interrogate a data-
base of gene expression profiles for human medulloblastoma
samples (Pomeroy et al., 2002). Based on their gene expression
profiles, tumors were scored as having ‘‘low,’’ ‘‘medium,’’ or
‘‘high’’ expression of the CD15+ signature, and these groups
were compared to determine whether expression of the signa-
ture was associated with tumor subtype or patient survival.
Consistent with the immunohistochemical analysis above, we
found no significant correlation between CD15+ signature
expression and tumor subtype (data not shown). However, as
shown in Figure 7D, expression of the CD15 signature was
a strong predictor of patient survival: increased expression
was associated with shorter survival time (p = 0.021 based on
log-rank test for trend). When the same CD15 signature was
applied to a second, albeit smaller, data set (Thompson et al.,
2006), elevated expression was again associated with shorter
survival (Figure S7), although the results did not reach statistical
significance (p = 0.16). Together, these data indicate that
a subset of human tumors contain CD15+ cells and suggest
that the presence of a CD15+ gene expression signature may
be an important predictor of prognosis for human medulloblas-
toma.
DISCUSSION
The cancer stem cell hypothesis has gained a great deal of atten-
tion in recent years, with reports describing such cells in many
different types of human cancer. But to date, there have been
few studies of TPCs in animal models of the disease. In the
current study, we identify TPCs in the most commonly used
animal model of medulloblastoma, the Ptc mutant mouse. The
cells we describe differ from previously identified brain tumor
stem cells in that they do not express the stem cell marker
CD133 and cannot form neurospheres. Instead, they express
the neural progenitor marker Math1 and can be enriched based
on their expression of the carbohydrate antigen CD15. Trans-
plantation of Math1+CD15+ cells is sufficient to give rise to
tumors in 100% of hosts, and these tumors resemble the original
tumors in terms of histology and cellular heterogeneity. Based on
these findings, we conclude that the Math1+CD15+ compart-
ment contains TPCs.
The nature of the cells that initiate and propagate medulloblas-
toma has been a subject of debate for many years (Eberhart,
2007; Katsetos et al., 2003; Read et al., 2006). The fact that these
tumors are frequently found on the surface of the cerebellum and
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Gene Name Gene Symbol/Aliases Fold Change Gene Function
Proliferation/Self-Renewal
cyclin B1 Ccnb1 [ 2.4 G2/mitotic cyclin
ubiquitin-conjugating enzyme E2C Ube2c, UBCH10 [ 2.1 ubiquitination, cell-cycle regulation
cell division cycle 25 homolog C Cdc25c [ 2.1 phosphatase, regulates mitosis
cyclin B2 Ccnb2 [ 2.0 G2/mitotic cyclin
polo-like kinase 1 Plk1 [ 2.0 kinase, regulates cell-cycle checkpoints
aurora kinase A Aurka, Ark1, Stk6 [ 1.9 kinase, regulates spindle formation, cytokinesis
cyclin A2 Ccna2 [ 1.9 G1/S cyclin
discs large homolog 7 Dlgap5, Dlg7, HURP [ 1.8 regulates mitotic spindle formation
Notch2 Notch2 [ 1.8 receptor, regulates proliferation/self-renewal
Apoptosis
F-box protein 7 Fbxo7, Fbx7 Y 4.5 ubiquitin ligase, regulates apoptosis and cell cycle
cytoplasmic FMR1 interacting protein 2 Cyfip2, Pir121 Y 3.1 p53 target, promotes apoptosis
mitogen activated protein kinase 10 (JNK3) Mapk10, JNK3 Y 2.7 kinase, promotes apoptosis
harakiri, BCL-2-interacting protein Hrk, Bid3, DP5 Y 2.7 BH3-only protein, promotes apoptosis
SH3-domain kinase binding protein 1 Sh3kbp1, Ruk, CIN85 Y 2.5 adaptor, negative regulator of PI3-kinase
apoptosis-inducing factor Aifm3, Aifl Y 1.8 mitochondrial protein, inducer of apoptosis
baculoviral IAP repeat-containing 5 Birc5, Survivin, Api4 [ 1.9 prevents apoptosome assembly, inhibits apoptosis
Migration and Axon Growth
L1 cell adhesion molecule L1cam, CD171 Y 6.4 surface protein, regulates migration, neurite growth
G prot-regulated inducer of neurite outgrowth 3 Gprin3, Grin3 Y 5.3 cytoplasmic protein, binds G alpha subunits
dihydropyrimidinase-like 3 Dpysl3, Crmp4, ulip Y 4.9 cytoplasmic protein, involved in growth cone signaling
contactin 2 (TAG-1) Cntn2, Tag1 Y 3.3 surface protein, regulates neurite growth
semaphorin 6A Sema6a, Semaq Y 3.0 surface protein, regulates migration, neurite growth
doublecortin Dcx, Lisx Y 2.5 microtubule-binding protein, regulates migration
neuron-glia-CAM-related cell adhesion molecule Nrcam, Bravo Y 2.5 surface protein, regulates neurite growth
cyclin-dependent kinase 5, regulatory subunit Cdk5r1, p35 Y 2.2 kinase, regulates migration, axon growth, apoptosis
p21 (CDKN1A)-activated kinase 1 Pak1 Y 2.1 regulates cell motility and morphology
ephrin B2 Efnb2, Elf-2, Lerk5 Y 1.9 transmembrane protein, regulates migration
hyaluronan-mediated motility receptor Hmmr, Rhamm [ 2.3 surface/cytoplasmic protein, regulates motility
RNA Processing/Translation
bruno-like 5 Brunol5, Celf5 Y 3.0 RNA-binding protein, regulates differentiation
ELAV-like 4 (Hu antigen D) Elavl4, Hud Y 2.4 RNA-binding protein, regulates differentiation
ataxin 2-binding protein 1 A2bp1, Hrnbp1, Fox-1 Y 2.3 RNA-binding protein, regulates splicing in neurons
cytoplasmic polyA-binding protein 4 Cpeb4 Y 2.3 RNA-binding protein, regulates splicing in neurons
bruno-like 4 Brunol4, Celf4 Y 2.1 RNA-binding protein, regulates neural differentiation
trinucleotide repeat containing 4 Tnrc4, Brunol1, CAGH4 Y 1.9 RNA-binding protein, regulates splicing in neurons
Transcription/Differentiation
zinc finger protein, multitype 2 Zfpm2, Fog2 Y 3.3 binds transcription factors, regulates differentiation
nescient helix loop helix 1 Nhlh1, Nscl, Tal2 Y 3.1 bHLH transcription factor, regulates differentiation
transducin-like enhancer of split 2 Tle2, Grg2, Esg2 Y 2.7 corepressor, regulates Wnt, Notch signaling
neurogenic differentiation 1 Neurod1 Y 2.7 bHLH transcription factor, regulates differentiation
actin-like 6B Actl6b, Baf53b, ArpNa Y 2.5 chromatin remodeling protein, regulates differentiation
scratch homolog 2, zinc finger protein Scrt2 Y 2.2 Snail family transcriptional repressor
Kru¨ppel-like factor 7 Klf7, Uklf Y 2.0 Zn-finger transcription factor, regulates differentiation
Kru¨ppel-like factor 12 Klf12, AP-2rep Y 1.9 Zn-finger transcriptional repressor
Expression of 438 genes differed significantly between CD15+ and CD15 cells (Table S1). Based on Gene Ontology (Table S2) and literature searches,
many genes could be grouped into five categories. Representative genes from each category are listed. Gene names and symbols are from the Entrez
Gene database. Fold change represents difference in expression in CD15+ versus CD15 cells; genes increased in CD15+ cells are preceded by an up
arrow ([); those decreased in CD15+ cells are preceded by a down arrow (Y). Gene functions are based on published literature, with emphasis placed
on functions in the nervous system. For references supporting functions of each gene, see Table S3 and Supplemental References.
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Increased Proliferation and Hh Pathway
Activation
(A) CD15+ and CD15 tumor cells were cultured
for 48 hr in serum-free medium and then pulsed
with tritiated thymidine (3H-Td) for 14 hr before as-
saying thymidine incorporation. Data represent
means of triplicate samples ± SEM.
(B and C) RNA from CD15+ and CD15 tumor cells
was analyzed by real-time RT-PCR using primers
specific for the Hh target genes Cyclin D1 (B)
and Gli1 (C). Expression levels are normalized to
actin.
In (A)–(C), percentages of CD15+ cells are shown
below bars for each tumor. CD15+ cells consis-
tently exhibited higher proliferation and Hh target
gene expression than CD15 cells from the same
tumor.
(D) RNA from Math1+CD15+ and Math1+CD15
tumor cells and from wild-type (WT) granule
neuron precursors (GNPs) as a positive control
were analyzed by RT-PCR using primers specific
for Ptc exons 7–9 (found in both the mutant and
WT allele) and Ptc exons 2–3 (found only in the
WT allele). Transcripts containing exons 7–9
were found in all cell populations, but only GNPs
expressed transcripts containing the WT allele of
Ptc. These data suggest that both CD15+ and
CD15 cells are tumor cells that have lost the
WT allele.express markers associated with the granule lineage has led
many investigators to speculate that these tumors arise from
GNPs (Kadin et al., 1970; Miyata et al., 1998). On the other
hand, the demonstration that many medulloblastomas express
stem cell markers, form neurospheres, and are propagated by
CD133+ cells has raised the possibility that these tumors may
arise from, and be propagated by, neural stem cells (Hemmati
et al., 2003; Singh et al., 2003, 2004). Recent studies by our labo-
ratory and others (Schuller et al., 2008; Yang et al., 2008) have
shed light on the cell of origin for medulloblastoma, demon-
strating that Hh pathway activation in either stem cells or
GNPs can lead to medulloblastoma. But while these studies
provided insight into the normal cells that can give rise to tumors
(the cells of origin), they did not identify the cells critical for prop-
agation of tumors once they are established (the TPCs). In the
current study, we show that tumors from Ptc+/ mice are propa-
gated by GNP-like cells, and in particular, by a subset of these
cells that express CD15.
CD15 is expressed on both progenitors and stem cells in the
embryonic and adult central nervous system (Capela and
Temple, 2002, 2006). In light of this, one possible interpretation
of our findings is that CD15+ cells in Ptc+/ tumors might repre-
sent neural stem cell-like cells. However, several observations
argue against this notion. First, the fact that CD15 is expressed
on a subset of GNPs in the neonatal cerebellum (Figure S2; Mar-
ani and Tetteroo, 1983) indicates that CD15 expression is not
exclusive to stem cells. The fact that the CD15+ cells in our
tumors coexpress Math1, are unable to form neurospheres,
and show no evidence of multilineage differentiation also
suggests that these are not stem-like cells. Thus, we believe
that the CD15+ cells we have isolated are progenitor-like cells
with a unique capacity for tumor propagation.
CD15+ cells propagate tumors following transplantation, and,
when they represent a small subset of the cells in a tumor,
isolating them significantly enriches for tumor-propagating
capacity. However, it is important to note that CD15+ cells some-
times represent a fairly large fraction of the tumor. The high
percentage of cells expressing a marker of TPCs is not unprec-
edented: in human brain tumors, CD133 has been reported to be
found on up to 40% of cells (Singh et al., 2003, 2004). Whether
this means that a large percentage of cells in the tumor are
capable of tumor propagation (Kelly et al., 2007), or whether
the true TPCs represent a subset of the CD133+ or CD15+ cells,
will need to be examined by subfractionating each population
with additional markers.
To investigate the molecular basis for the tumor-propagating
capacity of CD15+ cells, we performed microarray analysis on
CD15+ and CD15 cells from Ptc+/ tumors. This analysis re-
vealed that CD15+ cells have a distinct gene expression profile
characterized by increased expression of genes associated
with proliferation and self-renewal and decreased expression
of genes involved in apoptosis and differentiation. Consistent
with this expression profile, we also observed that CD15+ cells
are more proliferative than CD15 cells, both in vitro and
in vivo. This property distinguishes CD15+ cells from the TPCs
found in human leukemia, which are more quiescent than the
bulk of the tumor (Bonnet and Dick, 1997; Holyoake et al.,
1999). On the other hand, CD133+ cells from human brain
tumors have been reported to be more proliferative than their
CD133 counterparts (Singh et al., 2004), perhaps indicating
a distinction between TPCs in the nervous and hematopoietic
systems. Interestingly, we have found that CD15+ cells in the
neonatal cerebellum also have higher proliferative capacity or
higher intrinsic Hh responsiveness than CD15 cells. It is
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cells and retain this proliferative capacity. Alternatively, it is
possible that tumor cells acquire these properties and concom-
itantly acquire expression of CD15. Further studies will be
necessary to determine the relationship between normal and
neoplastic CD15+ cells and the mechanisms that regulate
CD15 expression.
Our observation that CD15+ cells recapitulate the heteroge-
neity within the original tumor and in particular generate CD15+
as well as CD15 cells suggests that these cells may sit at the
top of a hierarchy of differentiation within the tumor. Although
our data indicate that many CD15 cells represent tumor cells
(based on expression of Math1 and loss of Ptc), these cells
appear to be less proliferative than their CD15+ counterparts.
However, as shown in Figure 6 and Figure S5, these cells are
not completely quiescent. Indeed, since CD15 cells are
frequently much more abundant than CD15+ cells, they may
contribute substantially to the growth of tumors in vivo. In the
context of a rapidly growing tumor, it may be critical to eliminate
both the TPCs and their more differentiated progeny in order to
effectively eradicate the tumor.
The identification of CD15 as a marker for TPCs in a mouse
model of medulloblastoma raises the question of whether it is
relevant for human medulloblastoma as well. Our observation
that CD15 is expressed in a subset of human medulloblastomas
is consistent with this possibility. Since we identified CD15 as
a marker of TPCs in tumors from Ptc+/ mice, which are thought
to be genetically similar to human nodular/desmoplastic medul-
loblastomas (Goodrich et al., 1997; Pietsch et al., 1997; Pomeroy
et al., 2002), we expected that CD15 expression might be more
common in this subtype of tumor. However, our immunohisto-
chemical and flow cytometric analysis suggest that CD15
expression is not restricted to such tumors and can occur in
a variety of medulloblastoma subtypes. These findings indicate
that tumor morphology and the presence of Hh pathway muta-
tions may not be critical determinants of CD15 expression and
Figure 7. CD15 Is Expressed in Human Medulloblas-
toma, and Expression of a CD15-Associated Gene
Signature Predicts Survival
(A) Variable immunoreactivity for CD15 in a classic medullo-
blastoma.
(B) CD15 immunoreactivity in the matrix of a nodule in a medul-
loblastoma with extensive nodularity.
(C) Strong immunoreactivity for CD15 in clusters of tumor cells
in a large cell medulloblastoma. Scale bars in (A)–(C) = 70 mm.
(D) Increased probability of CD15+ signature correlates with
poor survival in human medulloblastoma. Black tick marks
represent surviving patients at time of last follow-up. Log-
rank for trend, p = 0.02.
suggest that the role of CD15 should be investi-
gated in all medulloblastoma subtypes.
Support for the notion that CD15 may have
significance in human medulloblastoma comes
from our demonstration that a CD15+ gene expres-
sion signature can predict survival in medulloblas-
toma patients. One interpretation of this finding is
that tumors with strong expression of the CD15+
signature contain a large percentage of CD15+ cells, and that
having many such cells makes them particularly aggressive.
Alternatively, it is possible that expression of the CD15+ signa-
ture reflects not expression of CD15 itself but rather the pres-
ence of properties (increased proliferative capacity, decreased
tendency to differentiate or die) that are associated with CD15+
cells. In either case, the signature that we have derived from
our studies of TPCs in mice may be a valuable tool for predicting
outcome in human medulloblastoma patients. Such tools are crit-
ical since most medulloblastoma patients are treated with an
aggressive regimen of radiation and chemotherapy; while this
results in high cure rates, it is associated with severe side effects
including cognitive deficits, endocrine disorders, and an increased
risk of secondary tumors. Stratification of patients based on
predictors of outcome such as the CD15+ signature may allow
clinicians to limit use of the most aggressive therapies to patients
with poor prognosis and to use less toxic but equally effective
treatments for patients whose prognosis is more favorable.
In summary, our studies identify a population of TPCs in
a mouse model of medulloblastoma. The fact that these cells
express markers of progenitors and cannot form neurospheres
indicates that TPCs need not resemble normal stem cells.
Rather, some tumors may be propagated by cells that resemble
neural progenitors. Identification of TPCs in a mouse model of
human medulloblastoma will allow us to study the mechanisms
by which they propagate tumors and to test approaches to tar-
geting them in vivo. Ultimately, such studies will be necessary
to determine whether eradication of TPCs cells is critical for
effective therapy of brain tumors.
EXPERIMENTAL PROCEDURES
Animals
Ptc+/ mice (Goodrich et al., 1997) were maintained by breeding with 129X1/
SvJ mice from The Jackson Laboratory. Math1-GFP/Ptc+/ mice were gener-
ated by crossing Ptc+/ mice with Math1-GFP mice (Lumpkin et al., 2003) from
144 Cancer Cell 15, 135–147, February 3, 2009 ª2009 Elsevier Inc.
Cancer Cell
Propagation of Medulloblastoma by CD15+ CellsJ. Johnson at the University of Texas Southwestern Medical Center. SCID/
beige mice were obtained from Taconic Farms. Mice were maintained in the
Cancer Center Isolation Facility at Duke University Medical Center, and all
experiments were performed using procedures approved by the Duke Univer-
sity IACUC.
Stereotaxic Implantation of Tumor Cells
SCID/beige mice were anesthetized using 100 mg/kg ketamine (Fort Dodge
Animal Health) plus 9 mg/kg xylazine (Ben Venue Laboratories) and positioned
in a stereotaxic frame with a mouse adaptor (David Kopf Instruments). An inci-
sion was made in the midline of the scalp over the cerebellum, and a small hole
was made in the skull (1 mm lateral to midline) using a beveled (sharp point)
18G needle. A 24G Hamilton syringe loaded with cells was mounted on
a micromanipulator and introduced through the hole at a 30 angle to the
surface of the cerebellum, at a depth of 1 mm. Freshly sorted (uncultured) cells
were injected over the course of 2 min, and the needle was left in place for
another 2 min to avoid reflux. After removing the mouse from the frame, 1–2
drops of 0.25% (2.5 mg/ml) bupivicaine (Hospira) were applied along the
incision for postoperative analgesia, and the skin was closed with 6-0 fast-
absorbing plain gut suture using a 3/8 PC-1 cutting needle (Ethicon).
Antibodies
Antibodies used for FACS and immunostaining included CD15 (clone MMA),
CD57/HNK-1, CD24 (clone 30F1), CD117/c-kit (clone 2B8), and anti-BrdU-
APC from BD Biosciences; CD44 (clone IM7) and Sca-1 (clone D7) from eBio-
science; CD133 (clone 13A4), PSA-NCAM (clone 2-2B), and A2B5 (clone
A2B5-105) from Millipore; GD3 (Clone R24) from EMD Biosciences;
anti-BrdU (rat IgG) from Abcam; and anti-Ki67 (Clone TEC-3) from Dako.
Secondary antibodies included fluorescein (DTAF)- or phycoerythrin-conju-
gated F(ab0)2 fragments of goat-anti-mouse IgM or goat-anti-mouse IgG
(Jackson ImmunoResearch) and anti-rat IgG Alexa Fluor 568 and anti-mouse
IgM-Alexa Fluor 488 (Molecular Probes).
Cell and Tissue Staining
Dissociated tumor cells were plated in poly-D-lysine-coated chamber slides
for 6 hr prior to fixation in 4% paraformaldehyde (PFA) and blocking with
PBS + 10% normal goat serum. Anti-CD15 antibody was applied for 2 hr at
room temperature (RT), and Alexa Fluor 568-conjugated anti-mouse IgM
was applied for 1 hr at RT.
For staining of frozen tissue, brains were fixed in 4% PFA, cryoprotected in
25% sucrose, embedded in Tissue-Tek OCT (Sakura Finetek) and sectioned
sagittally at a thickness of 10 mm. Sections were permeabilized with PBST
(PBS + 0.1% Triton X-100), blocked with PBST + 10% normal goat serum,
and incubatedwith primaryantibodies for24hr at 4C and secondaryantibodies
for 1 hr at 37C. Sections were counterstained with DAPI (Molecular Probes) and
mounted in Fluoromount-G (Southern Biotechnology Associates). For detection
of BrdU-positive cells, animals were pulsed with BrdU before staining, and
sections were treated with DNase (Sigma) prior to antibody staining.
For staining of human and mouse paraffin sections, tissue was fixed over-
night in 10% formalin, transferred to 70% ethanol, paraffin embedded, and
sectioned at a thickness of 5 mm. Sections were stained with hematoxylin
and eosin (Sigma) or with hematoxylin and rat anti-mouse Ki67 (Dako) or
anti-CD15 (BD Biosciences). Ki67 was detected using biotinylated rabbit
anti-rat IgG followed by streptavidin-conjugated horseradish peroxidase and
DAB+ (Dako) as a chromogen. CD15 staining was visualized using a Ventana
IVIEW Detection kit (biotinylated Ig, Ventana Medical Systems). Sections were
mounted in permanent mounting medium and imaged using a Nikon TE200
inverted microscope and OpenLab software (Improvision).
Expression of CD15 in Human Medulloblastoma
Human medulloblastoma samples were obtained from tissue repositories at
Duke University Medical Center and St. Jude Children’s Research Hospital.
Informed consent was obtained from all patients prior to acquisition of tissue,
and patient identifying information was protected in accordance with the Duke
University and St. Jude institutional review boards. Immunohistochemical
analysis was performed on paraffin sections as described above.
Microarray Analysis
Ptc+/ tumor cells were sorted into CD15+ and CD15 populations, and RNA
was isolated, labeled, and hybridized to Affymetrix Mouse Genome 430 2.0
arrays. Microarray data were preprocessed using robust multichip analysis
(RMA). PCA and hierarchical clustering were performed with Partek Genomics
Suite 6.3. PCA was performed on samples based on normalized expression of
all genes. Unsupervised hierarchical clustering of differentially expressed
genes was carried out using average linkage, with Euclidean distance as the
similarity measurement. Genes differentially expressed between CD15+ and
CD15 samples were selected based upon both relative and statistical criteria
(1.8-fold change cutoff; pairwise t test false discovery rate [FDR] < 0.05).
Derivation of CD15+ Signature and Survival Analysis
The CD15+ signature was developed from gene expression differences
between CD15+ and CD15 tumor cells (n = 6 for each) using established
methods (Bild et al., 2006). Briefly, t tests and FDR estimates from RMA-post-
processed data (Bolstad et al., 2003) identified genes with the strongest levels
of differential expression. The expression profile of the gene set, termed
a ‘‘metagene,’’ is summarized by the top principle component of a singular
value decomposition (SVD) and then applied to a Bayesian probit regression
model to generate the signature. The internal accuracy of the predictive signa-
ture is assessed through proper leave-one-out cross-validation. For all anal-
ysis, SVD was performed using only training data. The CD15+ signature was
applied to three independent microarray data sets: (A) ten samples of CD15+
and CD15 tumor cells (n = 5 for each); (B) data from Pomeroy et al. (2002);
and (C) data from Thompson et al. (2006). During this process, the CD15+
signature was applied to each sample, and a probability of CD15+ status
was assigned with a range of 0 (CD15) to 1 (CD15+). For data sets B and C,
where the species differed between the training samples (murine) and the
test samples (human), Chip Comparer (http://tenero.duhs.duke.edu/
genearray/perl/chip/chipcomparer.pl) was used to find common probes
across species and microarray platforms, and FileMerger (http://tenero.
duhs.duke.edu/genearray/perl/filemerger.pl) was used to bring together the
training and test microarray data; all duplicate gene features were removed
prior to analysis.
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